Uterine fibroids are non-cancerous tumors that form within the uterus. While they are not normally dangerous, they can in some cases cause pain, discomfort, and abnormal bleeding. As fibroid growth is predominantly stimulated by the hormones estrogen and progesterone, it is understandable to assume that when hormone levels start to drop (around the onset of menopause) that any problematic fibroids will start to shrink or disappear – but is this really the case?
The Menopausal Dilemma
For many years, doctors would tell patients who were close to menopause and suffering from uterine fibroids to ‘hang in there’ and wait to see what happens. The problem with that theory was that very few patients with fibroids made it to menopause and instead, would undergo a hysterectomy to improve quality of life. So while falling levels of estrogen and progesterone might work in regard to reducing the size of fibroids, the hormonal imbalance a hysterectomy could cause would leave some women with a range of emotional and physical symptoms.
Getting Back To The ‘Wait And See’ Theory
Even when a hysterectomy isn’t necessary, the menopause can be a time of wildly fluctuating hormone levels. While levels of estrogen generally decrease as the process moves through the phases, during the perimenopause (the transitional period immediately before menopause) estrogen levels can see a dramatic upturn. As a result, there can be more estrogen present during this phase of the transition than at any time before. Clearly, this isn’t good for fibroids and may cause them to grow. Moreover, the time taken from perimenopause to menopause varies greatly for each person and as such, it can in some cases, take years to see a significant reduction in fibroid size.
So what is the best solution?
If you are in your 40’s and suffer from uterine fibroids, then, in reality, the best time to act is now. Given what we now know, it’s highly likely that adopting a ‘wait and see’ approach will result in further fibroid growth and worsening symptoms.
Uterine Fibroid Embolization.
An alternative approach is to undergo what is known as a Uterine Fibroid Embolization (UFE). It’s effectively a minimally invasive procedure which works by blocking the supply of blood to the fibroid. In doing so it causes the fibroid to shrink and any symptoms to be remedied.
UFE is recognized as an effective non-surgical treatment for fibroids and it provides women with a different approach other than a hysterectomy. It’s been suggested that around 90% of all women who have completed UFE therapy express feeling relief from fibroid symptoms leading to a better and higher quality of life. There are minimal complications (if any) and because it involves a small pinhole incision, patients can return to work or carry on their daily activities within a few days.
If you suffer from uterine fibroids and are seeking a safe, proven non-surgical way to eradicate fibroid problems then talk to us about UFE treatment. We offer free consultations so contact the team at MINT today. To book an appointment call us at 314 255 2204 .
Non-cancerous enlargement of the prostate gland can make life difficult and miserable for men. The condition known as benign prostatic hyperplasia is common in older men and can severely impact their quality of life. Learn who is a candidate for PAE.
The PAE procedure shrinks the prostate to improve urinary tract symptoms caused by benign prostatic hyperplasia (BPH). Once surgery was the only option to treat the condition, but today, patients are choosing PAE in increasing numbers.
J Community Hosp Intern Med Perspect. 2015; 5(1): 10.3402/jchimp.v5.25917.
Published online 2015 Feb 3. doi: 10.3402/jchimp.v5.25917
PMCID: PMC4318819
1Department of Internal Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, USA
Find articles by Rajesh Shrestha
2Department of Internal Medicine, Reading Health System, West Reading, PA, USA
Find articles by Raju Khanal
2Department of Internal Medicine, Reading Health System, West Reading, PA, USA
Find articles by Madan Raj Aryal
2Department of Internal Medicine, Reading Health System, West Reading, PA, USA
Find articles by Ranjan Pathak
2Department of Internal Medicine, Reading Health System, West Reading, PA, USA
Find articles by Paras Karmacharya
3Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA
Find articles by Muniba Naqi
3Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA
Find articles by Srujitha Murukutla
3Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA
Find articles by Vijaya Raj Bhatt
3Department of Internal Medicine, Staten Island University Hospital, New York, NY, USA
Find articles by Aaron Gottesman
Received 2014 Sep 3; Revised 2014 Nov 2; Accepted 2014 Nov 13.
Copyright © 2015 Rajesh Shrestha et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Uterine fibroid, one of the most common tumors in women, is estrogen dependent, which commonly regresses after menopause. Fibroid degeneration after menopause, therefore, is rare. Here the authors report a case of 56-year-old postmenopausal woman who presented with acute abdominal pain, low grade fever, and leukocytosis as a result of fibroid degeneration.
Keywords: post-menopause, uterine fibroid, degeneration, acute abdomen
Uterine fibroid is one of the most common tumors in women of reproductive age (1). The growth of the tumor is estrogen dependent (2); hence, it regresses and becomes clinically insignificant after menopause (1–3). Symptomatic fibroid degeneration after menopause, therefore, is extremely rare (4–6). Here we describe a case of fibroid degeneration in a postmenopausal woman which simulated surgical abdomen.
A 56-year-old postmenopausal woman presented to the emergency department with a 2-day history of intermittent, sharp, severe lower abdomen pain, most prominent over right flank. She complained of nausea but did not have any vomiting. She denied any urinary or bowel complaints as well as vaginal discharge or bleeding. She had history of multiple uterine fibroids in the past. She denied history of smoking, drinking, or any use of illicit drug. She was in a monogamous relationship with her husband. She did not have any positive past medical or surgical history, family history, or allergy history and was not taking any medication. On examination, she had a blood pressure of 151/86 mmHg, heart rate of 115/min, respiratory rate of 18/min, and temperature of 100.1°F. Abdominal examination revealed normal bowel sounds, firm abdomen, with palpable uterus above umbilicus and tenderness over the right lumbar region without any rebound tenderness. The rest of her physical examination was normal.
Laboratory evaluation revealed white count of 13,500/µL with 88% granulocytes; hemoglobin of 13.6 g/dL; platelet count of 185,000/µL; and normal glucose, electrolytes, amylase, lipase, renal, and liver functions. Urinalysis and chest radiographs were also normal. Computed tomography scan of abdomen and pelvis with oral and intravenous contrast (Fig. 1) showed enlarged uterus measuring up to 14.1 cm×9.7 cm with irregular and lobular contour, containing multiple uterine fibroids. There was 11.4 cm×8.2 cm heterogeneous exophytic fibroid with areas of calcifications, non-uniform enhancement with areas of irregular central necrosis, consistent with degenerating fibroid. There was perihepatic ascites as well as fluid in the Morison's pouch. Appendix was not seen, so appendicitis could not be ruled out. Patient was admitted with a diagnosis of fibroid degeneration. She was given nothing by mouth and started on intravenous normal saline infusion, hydromorphone, and metoclopramide as needed. Patient was also started on intravenous ciprofloxacin and metronidazole for possible acute appendicitis.
Approximately 16 hours after patient's admission, patient started complaining of worsening right upper and lower quadrant abdominal pain and tenderness. Repeat hemogram revealed worsening leukocytosis of 16,800/µL. Serum lactate level was normal. Right upper quadrant sonogram showed hepatomegaly, hepatic parenchymal echogenicity, and small amount of pericholecystic fluid. Patient was evaluated by gynecologists and surgeons, who attributed the condition to fibroid degeneration. Surgery was offered but the patient decided not to undergo surgery at that time. Next day, her white count further increased to 18,600/µL. The patient, however, felt better and remained hemodynamically stable and afebrile. Her urine and blood culture also turned out to be negative. The subsequent day, her white count dropped down to 17,500/µL. At this point, her antibiotics were discontinued and patient was started on oral diet. Patient was discharged home on oral analgesics on day 5. An outpatient elective hysterectomy was scheduled but cancelled because of upper respiratory tract infection. Three months from discharge, patient continues to do well and has decided against surgery.
Uterine fibroid is estrogen dependent (2); hence, it tends to regress and become clinically insignificant after menopause (1–3). There are rare case reports of postmenopausal hyaline (5) or cystic degeneration of fibroid (4, 6). These patients, however, presented with mass effects rather than acute abdomen. As illustrated by this case, degenerative changes can occur in fibroids after menopause and can present as acute abdomen, low grade fever, and leukocytosis, masquerading surgical abdomen.
Hyaline degeneration (63%) is the most common degenerative change in fibroid. Other degenerations include myxomatous changes (13%), calcification (8%), mucoid changes (6%), cystic degeneration (4%), red degeneration (3%), and fatty changes (3%) (7). Degenerative changes are considered to result from excessive growth that outmatches the blood supply, or mechanical compression of the feeder arteries. The increase in the size of fibroid as a result of hyaline or cystic degeneration is presumed to result from accumulation of extracellular matrix (5). Although the precise pathogenesis for degeneration of fibroids in postmenopausal women remains unclear, excessive production of growth factors (epidermal or insulin-like) from the fibroid might explain this condition. Additional studies are needed to shed light on this matter.
Although very rare, uterine leiomyosarcoma may arise from fibroid. Such malignant transformation occurs in middle aged to older women and should be considered in postmenopausal women with rapid enlargement of the fibroid (8). In this patient, an elective hysterectomy was scheduled which was cancelled because of patient preference. However, lack of further symptoms at 3-month follow-up is highly against such a possibility, given the aggressive nature of uterine leiomyosarcoma.
Fibroid degeneration can occur after menopause.
Acute abdominal pain, low grade fever, and leukocytosis can be the presenting feature, thus masquerading surgical acute abdomen.
The authors have not received any funding or benefits from industry or elsewhere to conduct this study.
1. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):615–26. [PubMed] [Google Scholar]
2. Houston KD, Hunter DS, Hodges LC, Walker CL. Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol Pathol. 2001;29(1):100–4. [PubMed] [Google Scholar]
3. Cramer SF, Marchetti C, Freedman J, Padela A. Relationship of myoma cell size and menopausal status in small uterine leiomyomas. Arch Pathol Lab Med. 2000;124(10):1448–53. [PubMed] [Google Scholar]
4. Low SC, Chong CL. A case of cystic leiomyoma mimicking an ovarian malignancy. Ann Acad Med Singapore. 2004;33(3):371–4. [PubMed] [Google Scholar]
5. Okamoto T, Koshiyama M, Yamamoto K. Rapidly growing leiomyoma in a postmenopausal woman. J Obstet Gynaecol Res. 2004;30(4):316–18. [PubMed] [Google Scholar]
6. Yarwood RL, Arroyo E. Cystic degeneration of a uterine leiomyoma masquerading as a postmenopausal ovarian cyst. A case report. J Reprod Med. 1999;44(7):649–52. [PubMed] [Google Scholar]
7. Persaud V, Arjoon PD. Uterine leiomyoma. Incidence of degenerative change and a correlation of associated symptoms. Obstet Gynecol. 1970;35(3):432–6. [PubMed] [Google Scholar]
8. Yanai H, Wani Y, Notohara K, Takada S, Yoshino T. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review. Pathol Int. 2010;60(7):506–9. [PubMed] [Google Scholar]
Articles from Journal of Community Hospital Internal Medicine Perspectives are provided here courtesy of Greater Baltimore Medical Center